HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort

被引：0
|
作者：
Lin, Mingxi
Luo, Ting
Zhang, Hui
Yang, Wentao
Zhang, Jian
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Sichuan Univ, West China Hosp, Breast Dis Ctr, Chengdu, Sichuan, Peoples R China
[3] Northwestern Univ, Dept Prevent Med, Div Biostat, Chicago, IL USA
[4] Fudan Univ, Dept Breast & Urol Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
[5] Fudan Univ, Shanghai Med Coll, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1021
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04
    Prat, Aleix
    Modi, Shanu
    Tsurutani, Junji
    Cameron, David
    Harbeck, Nadia
    Garrido, Charo
    Karnoub, Maha
    Hsu, Ching
    Feng, Wenquin
    Yung, Lotus
    Wang, Yibin
    Gambhire, Dhiraj
    Ford, Shirin K.
    Vitazka, Patrik
    Ueno, Naoto T.
    CANCER RESEARCH, 2023, 83 (05)
  • [22] Determination of HER2-Low Status in Tumors of Patients With Unresectable and/or Metastatic Breast Cancer in DESTINY-Breast04
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 8 - 9
  • [23] HER2-low metastatic breast cancer: molecular insights and therapeutic strategies
    Esteva, Francisco J.
    Jaffer, Shabnam
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2023, 9
  • [24] DISCORDANCE IN TRIPLE-RECEPTOR STATUS BETWEEN PRIMARY AND RECURRENT BREAST CANCER
    Matsumoto, Akiko
    Takahashi, Maiko
    Hayashida, Tetsu
    Jinno, Hiromitsu
    Kitagawa, Yuko
    BREAST, 2013, 22 : S59 - S59
  • [25] Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm
    Yang, Charlie
    Brezden-Masley, Christine
    Joy, Anil Abraham
    Sehdev, Sandeep
    Modi, Shanu
    Simmons, Christine
    Henning, Jan-Willem
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [26] Impact of HER2-Low Status in Metastatic Gastric Cancer: A Real-World Retrospective Cohort Study
    Unal, Olcun Umit
    Akay, Seval
    Gul, Gurkan
    Keser, Murat
    Ozamrak, Birsen Gizem
    Solakoglu Kahraman, Dudu
    Erdogan, Mihriban
    ONCOLOGY, 2024, 102 (10) : 889 - 896
  • [27] Real-world data of HER2-low metastatic breast cancer: A population based cohort study
    Holthuis, Emily I.
    Vondeling, Gerard T.
    Kuiper, Josephina G.
    Dezentje, Vincent
    Rosenlund, Mats
    Overbeek, Jetty A.
    van Deurzen, Carolien H. M.
    BREAST, 2022, 66 : 278 - 284
  • [28] Safety and Efficacy of Trastuzumab Deruxtecan for Metastatic HER2+and HER2-low Breast Cancer
    Qureshi, Zaheer
    Altaf, Faryal
    Jamil, Abdur
    Siddique, Rimsha
    Fatima, Eeshal
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (11): : 535 - 541
  • [29] The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status
    Horisawa, Nanae
    Adachi, Yayoi
    Takatsuka, Daiki
    Nozawa, Kazuki
    Endo, Yuka
    Ozaki, Yuri
    Sugino, Kayoko
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    BREAST CANCER, 2022, 29 (02) : 234 - 241
  • [30] The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status
    Nanae Horisawa
    Yayoi Adachi
    Daiki Takatsuka
    Kazuki Nozawa
    Yuka Endo
    Yuri Ozaki
    Kayoko Sugino
    Ayumi Kataoka
    Haruru Kotani
    Akiyo Yoshimura
    Masaya Hattori
    Masataka Sawaki
    Hiroji Iwata
    Breast Cancer, 2022, 29 : 234 - 241
12345